Biography for Damian Garde
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
Boston's Constant Therapy is at work on a cloud-based iPad app for patients undergoing brain rehabilitation, and the startup has wrapped up its first funding round.
Neuromodulation devices have been key to Boston Scientific's years-long effort to reverse its lagging fortunes, and now the med tech giant has teamed up with two European nonprofits to promote its treatments for Parkinson's disease and dystonia.
Japanese medical device giant Terumo has inked a deal with CareFusion to jump-start U.S. sales of its IV catheters, counting on its partner's experience and share of the market to boost its stateside revenue.
Illumina boosted its revenue 24% last year thanks to an expanded share of the gene-sequencing market and a deeper dive into diagnostics, and now, thanks in part to the launch of $1,000 genome technology, the company has big expectations for 2014.
While the surprise flop of Medtronic's market-leading renal denervation device spurred a domino effect on other players in the field, California startup ReCor Medical has no plans to delay its program, affirming its commitment to a device that takes a different approach to lowering blood pressure.
Edwards Lifesciences' days atop the heart-valve space may be numbered, but the California devicemaker is making strides in Europe with the CE-mark approval for Sapien 3, the most advanced model of its market-leading technology.
Device giant Covidien posted a slight boost in sales last quarter, as the recently pharma-free company prepares for what promises to be a transitional year.
The mid-makeover Endo Health Solutions has found a buyer for the rest of its unwanted urology device business, selling HealthTronics to Altaris Capital Partners in a deal worth up to $130 million.
London's Lombard Medical is riding high on a spike in demand for its aortic repair device, and now the company has its heart set on a stateside IPO, planning to file with the SEC and swing for a spot on the Nasdaq.
Medtronic's market-leading renal denervation device failed to meet its primary efficacy endpoint in a pivotal trial, casting doubt over the company's vast and expensive development program and forcing the world's largest devicemaker to rethink its strategy.